Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors

Open Forum Infectious Diseases

Volumn 2, Issue 2, 2015, Pages

  De Luca, Andrea ^a,b   Di Giambenedetto, Simona ^b   Lo Presti, Alessandra ^c   Sierra, Saleta ^d   Prosperi, Mattia ^e   Cella, Eleonora ^c,f   Giovanetti, Marta ^c,g   Torti, Carlo ^h,i   Caudai, Cinzia ^j   Vicenti, Ilaria ^j   Saladini, Francesco ^j   Almi, Paolo ^a   Grima, Pierfrancesco ^k   Blanc, Pierluigi ^l   Fabbiani, Massimiliano ^b   Rossetti, Barbara ^a   Gagliardini, Roberta ^b   Kaiser, Rolf ^d   Ciccozzi, Massimo ^c,m   Zazzi, Maurizio ^j  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF FLORIDA   (United States)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h UNIVERSITY OF BRESCIA   (Italy)

ⁱ UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^j UNIVERSITY OF SIENA   (Italy)

^k Galatina   (Italy)

^l SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^m UNIVERSITY CAMPUS BIO MEDICO   (Italy)

more..

Author keywords

Drug resistance; Genotype 1a; HCV; Protease; Q80K

Indexed keywords

HEPACIVIRIN INHIBITOR; NONSTRUCTURAL PROTEIN 3; SIMEPREVIR; SOFOSBUVIR;

ARTICLE; BAYES THEOREM; CLADISTICS; GENE MUTATION; GENE SEQUENCE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1A; HOST RESISTANCE; HUMAN; NONHUMAN; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 84979964663     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv043     Document Type: Article

References (48)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107-15.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67.
3. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3:47-52.
4. Zignego AL, Gragnani L, Di Pietro E, et al. HCV infection, malignancy, and liver transplantation. Transplant Proc 2003; 35:1032-3.
5. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146:1176-92.
6. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59:318-27.
7. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61:77-87.
8. Li YP, Ramirez S, Humes D, et al. Differential sensitivity of 5'UTRNS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology 2014; 146:812-21.e4.
9. Ng T, Reisch T, Middleton T, et al. ABT-493, a potent HCV NS3/4A protease inhibitor with broad genotype coverage. In: 21st Conference on Retroviruses and Opportunistic Infections. Boston, MA, March 3-6, 2014 (Abstract 636).
10. deLemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med 2014; 20:315-21.
11. Wyles DL, Gutierrez JA. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. J Viral Hepat 2014; 21:229-40.
12. Alves R, Queiroz AT, Pessoa MG, et al. The presence of resistance mutations to protease and polymerase inhibitors in hepatitis C virus sequences from the Los Alamos databank. J Viral Hepat 2013; 20:414-21.
13. Bae A, Sun SC, Qi X, et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 2010; 54:5288-97.
14. Asselah T, Marcellin P. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int 2014; 34(Suppl 1):60-8.
15. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756-65.
16. Olysio. EMA/CHMP/137969/2014 Committee for Medicinal Products for Human Use (CHMP), 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_Initial_authorisation/human/002777/WC500163524.pdf. Accessed 21 April, 2015.
17. Olysio. U.S. Food and Drug Administration. Reference ID: 3417522, 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf. Accessed 21 April, 2015.
18. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed 30 November 2014.
19. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60:392-420.
20. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res 2014; 105:64-71.
21. Pickett BE, Striker R, Lefkowitz EJ. Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 2011; 18:608-18.
22. Vicenti I, Rosi A, Saladini F, et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 2012; 67:984-7.
23. Peres-da-Silva A, Almeida AJ, Lampe E. Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs. Mem Inst Oswaldo Cruz 2012; 107:254-61.
24. Wyles DL. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med 2012; 20: 139-45.
25. Ciccozzi M, Vujoševic D, Lo Presti A, et al. Genetic diversity of HIV type 1 in Montenegro. AIDS Res Hum Retroviruses 2011; 27:921-4.
26. Posada D, Buckley TR. Model selection and model averaging in phylogenetics: advantages of Akaike information criterion and bayesian approaches over likelihood ratio tests. Syst Biol 2004; 53:793-808.
27. Lo Presti A, Ciccozzi M, Cella E, et al. Origin, evolution, and phylogeography of recent epidemic CHIKV strains. Infect Genet Evol 2012; 12:392-8.
28. Sierra S, Kaiser R, Lübke N, et al. Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach. J Vis Exp 2011; 58:3264.
29. Van de Vijver DA, Wensing AM, Angarano G, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 41:352-60.
30. Holmes EC, Nee S, Rambaut A, et al. Revealing the history of infectious disease epidemics through phylogenetic trees. Philos Trans R Soc Lond B Biol Sci 1995; 349:33-40.
31. Drummond AJ, Rambaut A, Shapiro B, et al. Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol 2005; 22:1185-92.
32. Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 2007; 7:214.
33. Kass RE, Raftery AE. Bayes factors. J Am Stat Assoc 1995; 90:773-95.
34. Pond SK, Muse SV. Site-to-site variation of synonymous substitution rates. Mol Biol Evol 2005; 22:2375-85.
35. Nielsen R, Yang Z. Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 1998; 148:929-36.
36. Pond SL, Frost SD. A simple hierarchical approach to modelling distributions of substitution rates. Mol Biol Evol 2005; 22:223-34.
37. Magiorkinis G, Magiorkinis E, Paraskevis D, et al. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med 2009; 6:e1000198.
38. Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54:1878-87.
39. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-29.
40. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384:414-26.
41. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-41.e6.
42. McCloskey RM, Liang RH, Joy JB, et al. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. J Infect Dis 2014; 211:1288-95.
43. De Luca A, Bianco C, Rossetti B. Treatment of HCV infection with the novel NS3/4A protease inhibitors. Curr Opin Pharmacol 2014; 18C: 9-17.
44. Cento V, Mirabelli C, Salpini R, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One 2012; 7:e39652.
45. Larrey D, Lohse AW, de Ledinghen V, et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012; 57:39-46.
46. Zeuzem S, Asselah T, Angus P. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141:2047-55.
47. Lambert SM, Langley DR, Garnett JA, et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci 2014; 23:723-34.
48. Everson GT, Dusheiko G, Coakley E, et al. Integrated efficacy analysis of four phase 3 studies in HCV genotype 1a-infected patients treated with ABT 450/r/ombitasvir and dasabuvir with or without ribavirin. 65th Annual Meeting of the American Association for the Study of Liver Diseases, United States of America, Boston, 7-11 November 2014, (Abstract 83).